WallStreetZenWallStreetZen

NYSE: MANE
Veradermics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MANE

Based on 5 analysts offering 12 month price targets for Veradermics Inc

Min Forecast
$135.00+1.04%
Avg Forecast
$170.60+27.69%
Max Forecast
$204.00+52.68%

Should I buy or sell MANE stock?

Based on 6 analysts offering ratings for Veradermics Inc.

Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MANE's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates MANE as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their MANE stock forecasts and price targets.

MANE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-22Find Out Why
lockedlocked$00.00+00.00%2026-10-19
lockedlocked$00.00+00.00%2026-10-19
lockedlocked$00.00+00.00%2026-07-16Find Out Why
lockedlocked$00.00+00.00%2026-07-07Find Out Why
LifeSci Capital
Bottom 50%
50
BuyInitiates Coverage On$135.00+4.22%2026-06-16

1 of 1

Forecast return on equity

Is MANE forecast to generate an efficient return?

Company
-6.18%
Industry
14.98%
Market
172.55%
MANE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MANE forecast to generate an efficient return on assets?

Company
-6.09%
Industry
21.21%
MANE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MANE earnings per share forecast

What is MANE's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$2.92
Avg 2 year Forecast
-$2.69
Avg 3 year Forecast
-$2.67

MANE revenue forecast

What is MANE's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$8.8M
Avg 3 year Forecast
$69.2M

MANE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MANE$129.53$170.60+31.71%Strong Buy
CGON$61.96$87.50+41.22%Strong Buy
MIRM$85.74$152.27+77.60%Strong Buy
SRRK$42.91$70.30+63.83%Strong Buy
COGT$29.73$54.25+82.48%Strong Buy
View Top Biotech Stocks

Veradermics Stock Forecast FAQ

Is Veradermics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NYSE: MANE) stock is to Strong Buy MANE stock.

Out of 6 analysts, 4 (66.67%) are recommending MANE as a Strong Buy, 2 (33.33%) are recommending MANE as a Buy, 0 (0%) are recommending MANE as a Hold, 0 (0%) are recommending MANE as a Sell, and 0 (0%) are recommending MANE as a Strong Sell.

If you're new to stock investing, here's how to buy Veradermics stock.

What is MANE's earnings growth forecast for 2026-2028?

(NYSE: MANE) Veradermics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.68%.

Veradermics's earnings in 2026 is N/A.On average, 8 Wall Street analysts forecast MANE's earnings for 2026 to be -$122,156,762, with the lowest MANE earnings forecast at -$127,830,504, and the highest MANE earnings forecast at -$114,498,463. On average, 8 Wall Street analysts forecast MANE's earnings for 2027 to be -$112,279,937, with the lowest MANE earnings forecast at -$128,444,672, and the highest MANE earnings forecast at -$87,738,286.

In 2028, MANE is forecast to generate -$111,540,429 in earnings, with the lowest earnings forecast at -$162,140,352 and the highest earnings forecast at -$49,572,131.

What is MANE's revenue growth forecast for 2026-2028?

(NYSE: MANE) Veradermics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.59%.

Veradermics's revenue in 2026 is N/A.On average, 7 Wall Street analysts forecast MANE's revenue for 2026 to be $0, with the lowest MANE revenue forecast at $0, and the highest MANE revenue forecast at $0. On average, 8 Wall Street analysts forecast MANE's revenue for 2027 to be $368,960,381, with the lowest MANE revenue forecast at $0, and the highest MANE revenue forecast at $2,278,855,738.

In 2028, MANE is forecast to generate $2,891,060,071 in revenue, with the lowest revenue forecast at $1,605,025,705 and the highest revenue forecast at $4,913,343,994.

What is MANE's forecast return on assets (ROA) for 2026-2029?

(NYSE: MANE) forecast ROA is -6.09%, which is lower than the forecast US Biotechnology industry average of 21.67%.

What is MANE's Price Target?

According to 5 Wall Street analysts that have issued a 1 year MANE price target, the average MANE price target is $170.60, with the highest MANE stock price forecast at $204.00 and the lowest MANE stock price forecast at $135.00.

On average, Wall Street analysts predict that Veradermics's share price could reach $170.60 by Oct 22, 2027. The average Veradermics stock price prediction forecasts a potential upside of 31.71% from the current MANE share price of $129.53.

What is MANE's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: MANE) Veradermics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that MANE's EPS will be -$2.92 for 2026, with the lowest EPS forecast at -$3.06, and the highest EPS forecast at -$2.74. On average, analysts forecast that MANE's EPS will be -$2.69 for 2027, with the lowest EPS forecast at -$3.07, and the highest EPS forecast at -$2.10. In 2028, MANE's EPS is forecast to hit -$2.67 (min: -$3.88, max: -$1.19).

What is MANE's forecast return on equity (ROE) for 2026-2029?

(NYSE: MANE) forecast ROE is -6.18%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.